RxDoctor Payments DataLook up a doctor →

Neil Ettinger, MD

Pulmonary Disease · Chesterfield, MONPI 1619086451

Payments from drug & device makers

$3,476,114in general payments, 2019–2025

Across 1,741 payments — averaging $1996.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$816K
  • Boehringer Ingelheim$580K
  • United Therapeutics Corporation$458K
  • Roche Products Limited$435K
  • E.r. Squibb & Sons, L.L.C.$319K
  • Genentech, Inc.$155K
  • plus $714K from 54 others
$141in research payments, 2019–2025

Across 1 payment — averaging $140.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$141

What the payments were for

  • Speaking & faculty fees$52,40574%
  • Travel & lodging$1,8613%
  • Food & beverage$16,54823%
  • Education$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron59$815,736
Boehringer Ingelheim215$580,193
United Therapeutics Corporation193$457,672
Roche Products Limited50$434,508
E.r. Squibb & Sons, L.L.C.25$319,324
Genentech, Inc.50$154,651
GSK197$134,340
Biogen2$130,410
AstraZeneca111$121,823
Merck64$68,803
Bristol Myers Squibb4$63,940
Boehringer Ingelheim International GmbH184$47,759
Chiesi USA, Inc.11$44,345
Insmed, Inc.108$39,360
Hoffmann-la Roche Limited5$17,679
Sanofi US Services Inc.7$17,018
Sanofi29$11,489
Boehringer Ingelheim France S.a.s.55$8,101
Boehringer Ingelheim Limited13$1,446
Boehringer Ingelheim Pharma GmbH & Co.kg17$1,014
Regeneron Healthcare Solutions, Inc.26$755
Johnson & Johnson(2 entities)33$551
Actelion Pharmaceuticals US, Inc.31$501
Novartis23$399
Amgen20$389
Mylan Specialty L.p.23$374
Grifols USA, LLC18$355
Electromed, Inc.28$337
Genentech USA, Inc.21$309
Philips North America LLC12$308
Pfizer17$269
Baxter Healthcare5$213
Amarin Pharma, Inc.14$182
Tactile Systems Technology Inc6$176
Medtronic(2 entities)2$156
Intuitive Surgical2$155
ANI Pharmaceuticals, Inc.5$141
Gilead6$110
Viatris Specialty LLC5$102
Sunovion Pharmaceuticals Inc.8$95
Boston Scientific3$88
Verona Pharma, Inc.4$66
Resmed Corp3$49
Advanced Respiratory, Inc3$49
Phadia US Inc.2$46
Teva Pharmaceuticals USA, Inc.3$42
Harmony Biosciences LLC1$34
Axsome Therapeutics, Inc.2$33
Nabriva Therapeutics, PLC2$30
Paratek Pharmaceuticals, Inc.1$21
Vifor Pharma, Inc.1$17
Sanofi Pasteur Inc.1$16
Azurity Pharmaceuticals, Inc.1$16
Sanofi-aventis U.S. LLC1$16
Takeda Pharmaceuticals U.S.A., Inc.1$14
ERBE USA Inc1$13
Kowa Pharmaceuticals America, Inc.1$13
Inari Medical, Inc.1$12
Covis Pharma GmbH1$12
Bayer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,476,114 in reported general payments places this provider in the 95th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$317,340
Medicare patients
1,114
Services billed
3,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate197$2,664,433
Trelegy ElliptaFluticasone/Umeclidin/Vilanter914$771,659
OpsumitMacitentan46$589,268
Pirfenidone100$230,517
Breo ElliptaFluticasone/Vilanterol229$151,188
Breztri AerosphereBudesonide/Glycopyr/Formoterol96$78,348
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr106$70,601
XareltoRivaroxaban85$68,508
AdcircaTadalafil14$66,745
EliquisApixaban68$63,077
Spiriva RespimatTiotropium Bromide64$54,544
Combivent RespimatIpratropium/Albuterol Sulfate44$32,952
Incruse ElliptaUmeclidinium Bromide59$32,261
SymbicortBudesonide/Formoterol Fumarate69$22,291
NeuproRotigotine15$19,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$580,193$2,751,929305 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$134,340$1,033,5861,333 claims
Actelion Pharmaceuticals US, Inc.Opsumit$501$589,26846 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$121,823$104,673176 claims
Johnson & JohnsonXarelto$551$68,50885 claims
United Therapeutics CorporationAdcirca$457,672$66,74514 claims
PfizerEliquis, Abrysvo$269$65,99979 claims
Covis Pharma GmbHAlvesco$12$12,68622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Chesterfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →